Acute Myeloid Leukemia Market Report: Dynamics, Forecast, Competitive Assessment., Key Updates on Mylotarg and more
The Acute Myeloid Leukemia (AML) Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the proj
(EMAILWIRE.COM, April 03, 2018 ) Acute Myeloid Leukemia (AML) is a disease that has been characterized by a stagnant pipeline and, consequently, the treatment paradigm has not substantially changed over time. Since the 1970s, the standard of care in newly diagnosed fit patients has been a chemotherapy bases 7 + 3 induction regimen (seven days of cytarabine + three days of an anthracycline), aimed at achieving a complete hematologic remission (CR), followed by consolidation therapy with cytarabine, or an allogeneic hematopoietic cell transplantation (HCT). In the last decade, a better understanding of the molecular basis of AML has encouraged the development of new targeted therapies, and this led to the launch of the first targeted agents in 2017. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AML space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.
Access Report Here: https://www.themarketreports.com/report/acute-myeloid-leukemia-aml-dynamic-market-forecast-to-2026
Acute Myeloid Leukemia (AML)-Dynamic Market Forecast to 2026 report provide details about recent regulatory events along with recent commercial events and recent clinical events. Further this report talks about new SOC expected for elderly t-AML and AML-MRC patients, adoption of the first FLT3 inhibitor, Rydapt, in the US and EU, Lack of competition in the IDH+ AML market segment benefits celgene and agios and US approval of the first CD33 targeting agent, Mylotarg.
Components of the slide deck include -
• Timeline of market-impacting events
• Key clinical trial landscape updates
• Conference coverage
• Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
• Overview of updates to the forecast model based on anticipated future impact of events
• Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018
Purchase Link: https://www.themarketreports.com/report/buy-now/987800
Table of Contents:
1. Dynamic Market Forecast Overview
2. Executive Summary
3. Conference Coverage - ASH 2017
4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
7. Event 4: US Approval of the First CD33 Targeting Agent, Mylotarg
8. Additional Events
9. Other Events of Interest
10. Events Calendar
11. Appendix
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/987800
Acute Myeloid Leukemia Market Report: Dynamics, Forecast, Competitive Assessment., Key Updates on Mylotarg and more
Access Report Here: https://www.themarketreports.com/report/acute-myeloid-leukemia-aml-dynamic-market-forecast-to-2026
Acute Myeloid Leukemia (AML)-Dynamic Market Forecast to 2026 report provide details about recent regulatory events along with recent commercial events and recent clinical events. Further this report talks about new SOC expected for elderly t-AML and AML-MRC patients, adoption of the first FLT3 inhibitor, Rydapt, in the US and EU, Lack of competition in the IDH+ AML market segment benefits celgene and agios and US approval of the first CD33 targeting agent, Mylotarg.
Components of the slide deck include -
• Timeline of market-impacting events
• Key clinical trial landscape updates
• Conference coverage
• Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
• Overview of updates to the forecast model based on anticipated future impact of events
• Forward-looking events calendar listing expected key updates to the AML competitive space through December 2018
Purchase Link: https://www.themarketreports.com/report/buy-now/987800
Table of Contents:
1. Dynamic Market Forecast Overview
2. Executive Summary
3. Conference Coverage - ASH 2017
4. Event 1: New SOC expected for elderly t-AML and AML-MRC patients
5. Event 2: Adoption of the First FLT3 Inhibitor, Rydapt, in the US and EU
6. Event 3: Lack of Competition in the IDH+ AML Market Segment Benefits Celgene and Agios
7. Event 4: US Approval of the First CD33 Targeting Agent, Mylotarg
8. Additional Events
9. Other Events of Interest
10. Events Calendar
11. Appendix
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/987800
Acute Myeloid Leukemia Market Report: Dynamics, Forecast, Competitive Assessment., Key Updates on Mylotarg and more
Contact Information:
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results